Infection and diabetes

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 1017-1033

  Sentochnik, Deborah E ^a,c   Eliopoulos, George M ^b,d  

^a BASSETT HEALTHCARE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c Columbia University College of Physicians and Surgeons ^*  (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84971014002     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (234)

1. Robbins SL, Tucker AW Jr. The cause of death in diabetes: a report of 307 autopsied cases. . Engl J Med 1944;231:865-868.
2. Seymour A, Phear D. The causes of death in diabetes mellitus. A study of diabetic mortality in the Royal Adelaide Hospital from 1956 to 1960. Med J Aust 1963;1:890-894.
3. Sasaki A, Horiuchi N, Hasegawa K, et al. Mortality and causes of death in type 2 diabetic patients: a long-term follow-up study in Osaka District, Japan. Diabetes Res Clin Pract 1989;7:33-40.
4. Kessler II. Mortality experience of diabetic patients: a twenty-six year followup study. Am J Med 1971;51:715-724.
5. van der Meer JWM. Defects in host defense mechanisms. In: Rubin RR, Young LS, eds. Clinical approach to infection in the compromised host, 3rd ed. New York: Plenum Medical Book Company, 1994:33-66.
6. Perillie PE, Nolan JP, Finch SC. Studies of the resistance to infection in diabetes mellitus: local exudative cellular response. . Lab Clin Med 1962;59: 1008-1015.
7. Brayton RG, Stokes PE, Schwartz MS, et al. Effect of alcohol and various diseases on leukocyte mobilization phagocytosis and intracellular bacterial killing. . Engl J Med 1970;282:123-128.
8. Mowat AG, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. . Engl J Med 1971;284:621-627.
9. Molenaar DM, Palumbo PJ, Wilson WR, et al. Leukocyte chemotaxis in diabetic patients and their nondiabetic first-degree relatives. Diabetes 1976;25: 880-883.
10. Valerius NH, Eff C, Hansen NE, et al. Neutrophil and lymphocyte function in patients with diabetes mellitus. Acta Med Scand 1982;211:463-467.
11. Tater D, Tepaut B, Bercovicl JP, et al. Polymorphonuclear cell derangements in type I diabetes. Horm Metab Res 1987;19:642-647.
12. Naghibi M, Smith RP, Baltch AL, et al. The effect of diabetes mellitus on chemotactic and bactericidal activity of human polymorphonuclear leukocytes. Diabetes Res Clin Pract 1987;4:27-35.
13. Bybee JD, Rogers DE. The phagocytic activity of polymorphonuclear leukocytes obtained from patients with diabetes mellitus. . Lab Clin Med 1964;64: 1-13.
14. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 1974;23:9-15.
15. Rayfield EJ, Ault MJ, Keusch GT, et al. Infection and diabetes: the case for glucose control. Am J Med 1982;72:439-450.
16. Tan JS, Anderson JL, Watanakunakorn C, et al. Neutrophil dysfunction in diabetes mellitus. . Clin Lab Med 1975;85:26-33.
17. Nolan CM, Beaty HN, Bagdade JD. Further characterization of the impaired bactericidal function of granulocytes in patients with poorly controlled diabetes. Diabetes 1978;27:889-894.
18. Davidson J, Sowden JM, Fletcher J. Defective phagocytosis in insulin controlled diabetics: evidence for a reaction between glucose and opsonizing proteins. . Clin Pathol 1984;37:783.
19. Alexiewicz JM, Kumar D, Smogorzewski M, et al. Polymorphonuclear leukocytes in non-insulin-dependent diabetes mellitus: abnormalities in metabolism and function. Ann Intern Med 1995;123:919-924.
20. Peterson CM, Jones RL, Koenig RJ, et al. Reversible hematologic sequelae of diabetes mellitus. Ann Intern Med 1977;86:425-429.
21. Bagdade JD, Stewart M, Walters E. Impaired granulocyte adherence: a reversible defect in host defense in patients with poorly controlled diabetes. Diabetes 1978;27:677-681.
22. Bagdade JD, Walters E. Impaired granulocyte adherence in mildly diabetic patients: effects of tolazamide treatment. Diabetes 1980;29:309-311.
23. Andersen B, Goldsmith GH, Spagnuolo PJ. Neutrophil adhesive dysfunction in diabetes mellitus: the role of cellular plasma factors. . Lab Clin Med 1980;111:275-285.
24. Dziatkowiak H, Kowalska M, Denys A. Phagocytic and bactericidal activity of granulocytes in diabetic children. Diabetes 1982;31:1041-1043.
25. Repine JE, Clawson CC, Goetz FC. Bactericidal function of neutrophils from patients with acute bacterial infections and from diabetics. . Infect Dis 1980; 142:869-875.
26. Shah SV, Wallin JD, Eilen SD. Chemiluminescence and superoxide anion production by leukocytes from diabetic patients. . Clin Endocrinol Metab 1983;57: 402-409.
27. Wykretowicz A, Wierusz-Wysocka B, Wysocki J, et al. Impairment of the oxygen-dependent microbicidal mechanism of polymorphonuclear neutrophils in patients with type 2 diabetes is not associated with increased susceptibility to infection. Diabetes Res Clin Pract 1993;19:195-201.
28. Sato N, Kashima K, Uehara Y, et al. Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients. Diabetes Care 1997;20: 995-998.
29. Li YM. Glycation ligand binding motif in lactoferrin: implications in diabetic infection. Adv Exp Med Biol 1998;443:57-63.
30. Qvist R, Larkins RG. Diminished production of thromboxane B2 and prostaglandin E by stimulated polymorphonuclear leukocytes from insulin treated diabetic subjects. Diabetes 1983;32:622-626.
31. Jubiz W, Draper RE, Gale J, et al. Decreased leukotriene B4 synthesis by polymorphonuclear leukocytes from male patients with diabetes mellitus. Prostaglandins Leukotrienes Med 1984;14:305-311.
32. Geisler G, Almdal T, Bennedsen J, et al. Monocyte functions in diabetes mellitus. Acta Pathol Microbiol Immunol Scand 1982;90C:33-37.
33. Glass EJ, Stewart J, Matthews DM, et al. Impairment of monocyte "lectinlike" receptor activity in type I (insulin-dependent) diabetic patients. Diabetologia 1987;30:228-231.
34. Katz S, Klein B, Elian I, et al. Phagocytic activity of monocytes from diabetic patients. Diabetes Care 1983;6:479-482.
35. Hill HR, Augustine NH, Rallison ML, et al. Defective monocyte chemotactic response in diabetes mellitus. Clin Immunol 1983;3:70-77.
36. Setiadi H, Wautier J-L, Courilon-Mallet A, et al. Increased adhesion to fibronectin and MO-I expression by diabetic monocytes. . Immunol 1987;138: 3230-3234.
37. Kitahara M, Eyre HJ, Lynch RE, et al. Metabolic activity of diabetic monocytes. Diabetes 1980;29:251-256.
38. Offenbacher S, Salvi GE. Induction of prostaglandin release from macrophages by bacterial endotoxin. Clin Infect Dis 1999;28:505-513.
39. MacCuish AC, Urbaniak SJ, Campbell CJ, et al. Phytohemagglutinin transformation and circulating lymphocyte subpopulations in insulin-dependent diabetic patients. Diabetes 1974;25:908-912.
40. Casey JI, Heeter BJ, Klyshevich KA. Impaired response of lymphocytes of diabetic subjects to antigen of Staphylococcus aureus. J Infect Dis 1987;136: 495-501.
41. Casey J, Sturm C Jr. Impaired response of lymphocytes from non-insulindependent diabetics to staphage lysate and tetanus antigen. . Clin Microbiol 1982;15:109-114.
42. Speert DP, Silva J Jr. Abnormalities of in vitro lymphocyte response to mitogens in diabetic children during acute ketoacidosis. Am J Dis Child 1978;132: 1014-1017.
43. Kolterman OG, Olefsky JM, Kurahara C, et al. A defect in cell-mediated immune function in insulin-resistant diabetic and obese subjects. . Lab Clin Med 1980;96:535-543.
44. Topliss D, How J, Lewis M, et al. Evidence for cell-mediated immunity and specific suppressor T-lymphocyte dysfunction in Graves' disease and diabetes mellitus. . Clin Endocrinol Metab 1983;57:700-705.
45. Pozzilli P, Visalli N, Cavallo MG, et al. Normalization of the CD4/CD8 lym-phocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin. Diabetes Res 1987;6:51-56.
46. Faustman D, Eisenbarth G, Daley J, et al. Abnormal T-lymphocyte subsets in type I diabetes. Diabetes 1989;38:1462-1468.
47. Fisher BM, Smith JG, McCruden DC, et al. Responses of peripheral blood cells and lymphocyte subpopulations to insulin-induced hypoglycaemia in human insulin-dependent (type I) diabetes. Eur J Clin Invest 1987;17:208-213.
48. Kaye WA, Adri MN, Soelder JS, et al. Acquired defect in interleukin-2 production in patients with type I diabetes mellitus. . Engl J Med 1986;315: 920-924.
49. Giordano C, Galluzzo A, Marco A, et al. Increased soluble interleukin-2 receptor levels in the sera of type I diabetic patients. Diabetes Res 1988;8:135-138.
50. Negishi K, Gupta S, Chandy KG, et al. Interferon responsiveness of natural killer cells in type I human diabetes. Diabetes Res 1988;7:49-52.
51. McMillan DE. The microcirculation: changes in diabetes mellitus. Mayo Clin Proc 1988;63:517-520.
52. Vermes I, Steinmetz ET, Zeyen LJJM, et al. Rheological properties of white blood cells are changed in diabetic patients with microvascular complications. Diabetologia 1987;30:434-436.
53. Williamson JR, Tilton RG, Chang K, Kilo C. Basement membrane abnormalities in diabetes mellitus: relationship to clinical microangiopathy. Diabetes Metab Rev 1988;4:339-370.
54. Lehrer RI (moderator-UCLA conference). Mucormycosis. Ann Intern Med 1980;93:93-108.
55. Rippon JW. Zygomycosis. In: Medical mycology: the pathogenic fungi and the pathogenic Actinomycetes. Philadelphia: WB Saunders, 1988:681-713.
56. Brennan RO, Crain BJ, Proctor AM, et al. Cunninghamella: a newly recognized cause of rhinocerebral mucormycosis. Am J Clin Pathol 1983;80:98-102.
57. Waldorf AR, Ruderman N, Diamond RD. Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus. J Clin Invest 1984;74:150-160.
58. Waldorf AR. Host-parasite relationship in opportunistic mycoses. Crit Rev Microbiol 1986;13:133-172.
59. Gale GR, Welch AM. Studies of opportunistic fungi; inhibition of Rhizopus oryzae by human serum. Am J Med Sci 1961;241:604-612.
60. Artis WM, Fountain JA, Delcher HK, et al. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. Diabetes 1982;31:1109-1114.
61. Daly AL, Velazquez LA, Bradley SF, et al. Mucormycosis: association with deferoxamine therapy. Am J Med 1989;87:468-471.
62. Gregory JE, Golden A, Haymaker W. Mucormycosis of the central nervous system: a report of three cases. Bull Johns Hopkins Hosp 1943;73:405-419.
63. Marr TJ, Traismann HS, Davis T, et al. Rhinocerebral mucormycosis and juvenile diabetes mellitus: report of a case with recovery. Diabetes Care 1978;1: 250-251.
64. Lowe JT Jr, Hudson WR. Rhinocerebral phycomycosis and carotid internal artery thrombosis. Arch Otolaryngol 1975;101:100-103.
65. Rubin RH. Fungal infection in the compromised host. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. New York: Plenum Medical Book Co, 1988:203-204.
66. Oakley LA, Fisher JF, Dennison JH. Bread mold infection in diabetes: the lifethreatening condition of rhinocerebral zygomycosis. Postgrad Med 1986;80: 93-96.
67. Greenberg MR, Lippman SM, Grinnell VS, et al. Computed tomographic findings in orbital mucor. West J Med 1985;143:102-103.
68. Abramson E, Wilson D, Arky RA. Rhinocerebral phycomycosis, in association with diabetic ketoacidosis: report of two cases and a review of clinical and experimental experience with amphotericin B therapy. Ann Intern Med 1967;66:735-742.
69. Tierney MR, Baker AS. Infections of the head and neck in diabetes mellitus. Infect Dis Clin North Am 1995;9:195-216.
70. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on new triazoles. Antimicrob Agents Chemother 1988;32:1-8.
71. Hamill R, Oney LA, Crane LR. Successful therapy for rhinocerebral mucormycosis with associated bilateral brain abscesses. Arch Intern Med 1983;143:581-583.
72. Parfrey NA. Improved diagnosis and prognosis of mucormycosis: a clinicopathologic study of 33 cases. Medicine (Baltimore) 1986;65:113-123.
73. Koziel H, Koziel MJ. Pulmonary complications of diabetes mellitus. Pneumonia. Infect Dis Clin North Am 1995;9:65-96.
74. Bigby TD, Serota ML, Tierney LM Jr, et al. Clinical spectrum of pulmonary mucormycosis. Chest 1986;89:435-439.
75. Johnson GM, Baldwin JJ. Pulmonary mucormycosis and juvenile diabetes [Letter]. Am J Dis Child 1981;135:567-568.
76. Donohue JF. Endobronchial mucormycosis [Letter]. Chest 1983;83:585.
77. Chandler JR. Malignant external otitis. Laryngoscope 1968;78:1257-1294.
78. Zaky DA, Bentley DW, Lowy K, et al. Malignant external otitis: a severe form of otitis in diabetic patients. Am J Med 1976;61:298-302.
79. Salitt IE, Miller B, Wigmore M, et al. Bacterial flora of the external canal in diabetics and non-diabetics. Laryngoscope 1982;92:672-673.
80. Doroghazi RM, Nadol JP Jr, Hyslop NE Jr, et al. Invasive external otitis: report of 21 cases and review of the literature. Am J Med 1981;71:603-613.
81. Pelton SI, Klein JO. The draining ear. Otitis media and externa. Infect Dis Clin North Am 1988;2:117-129.
82. Rubin J, Yu VL. Malignant external otitis: insights into pathogenesis clinical manifestations: diagnosis and therapy. Am J Med 1988;85:391-398.
83. Corey JP, Levandowski RA, Panwalker AP. Prognostic implications of therapy for necrotizing external otitis. Am J Otol 1985;6:353-358.
84. Gherini SG, Brackmann DE, Bradley WG. Magnetic resonance imaging and computerized tomography in malignant external otitis. Laryngoscope 1986;96: 542-548.
85. Babiatzki A, Sandó J. Malignant external otitis. . Laryngol Otol 1987;101: 205-210.
86. Kraus DH, Rehm SJ, Kinney SE. The evolving treatment of necrotizing external otitis. Laryngoscope 1988;98:934-939.
87. Johnson MP, Ramphal R. Malignant external otitis: report on therapy with ceftazidime and review of therapy and prognosis. Rev Infect Dis 1990;12: 173-180.
88. Lang R, Goshen S, Kitzes-Cohen R, et al. Successful treatment of malignant external otitis with oral ciprofloxacin: report of experience with 23 patients. . Infect Dis 1990;161:537-540.
89. Leggett JM, Prendergast K. Malignant external otitis: the use of oral ciprofloxacin. J Laryngol Otol 1988;102:53-54.
90. Kelly HA, MacCallum WG. Pneumaturia. JAMA 1898;31:375.
91. Freiha FS, Messing EM, Gross DM. Emphysematous pyelonephritis. JCE Urol 1979;18:9.
92. Ahlering TE, Boyd SD, Hamilton CL, et al. Emphysematous pyelonephritis: a 5-year experience with 13 patients. . Urol 1985;134:1086-1088.
93. Zabbo A, Montie JE, Popowniak KL, et al. Bilateral emphysematous pyelonephritis. Urology 1985;25:293-296.
94. Michaeli J, Mogle P, Perlberg S, et al. Emphysematous pyelonephritis. . Urol 1984;131:203-208.
95. Cook DJ, Achong MR, Dobranowski J. Emphysematous pyelonephritis: complicated urinary tract infection in diabetes. Diabetes Care 1982;12:229-232.
96. Ouellet LM, Brook MP. Emphysematous pyelonephritis: an emergency indication for the plain abdominal radiograph. Ann Emerg Med 1988;17:722-724.
97. Hildebrand T-S, Nibbe L, Frei U, et al. Bilateral emphysematous pyelonephritis caused by Candida infection. Am J Kidney Dis 1999;33:E10.
98. Lowe FC, Walther JM. Case profile: emphysematous pyelonephritis. Urology 1986;28:532-533.
99. Sarmiento RV. Emphysematous cholecystitis: report of four cases and review of the literature. Arch Surg 1966;93:1009-1014.
100. Mentzer RM Jr, Golden GT, Chandler JG, et al. A comparative appraisal of emphysematous cholecystitis. Am J Surg 1975;129:10-15.
101. Schwartz SI. Gallbladder and extrahepatic biliary system. In: Schwartz SI, Shires GT, Spencer FC, et al., eds. Principles of surgery, 5th ed. New York: McGraw Hill, 1989:1381-1412.
102. Ruby ST, Gladstone A, Treat M, et al.. Emphysematous cholecystitis: a case report. JAMA 1983;249:248-249.
103. Nemcek AAJr, Gore RM, Vogelzang RL, et al. The effervescent gallbladder: a sonographic sign of emphysematous cholecystitis. AJR Am J Roentgenol 1980;150:575-593.
104. Hunter ND, Macintosh PK. Acute emphysematous cholecystitis: an ultrasonic diagnosis. AJR Am J Roentgenol 1980;134:592-593.
105. Del Favero G, Caroli A, Meggiato T, et al. Natural history of gallstones in non-insulin-dependent diabetes mellitus: a prospective 5-year follow-up. Dig Dis Sci 1994;39:1704-1707.
106. Ransohoff DF, Miller GL, Forsythe SB, et al. Outcome of acute cholecystitis in patients with diabetes mellitus. Ann Intern Med 1987;106:829-832.
107. Friedman LS, Roberts MS, Brett AS, et al. Management of asymptomatic gallstones in the diabetic patient: a decision analysis. Ann Intern Med 1988;109: 913-919.
108. Hickman MS, Schwesinger WH, Page CP. Acute cholecystitis in the diabetic: a case-control study of outcome. Arch Surg 1988;123:409-411.
109. Schwesinger WH, Diehl AK. Changing indications for laparoscopic cholecystectomy. Stones without symptoms and symptoms without stones. Surg Clin North Am 1996;76:493-504.
110. Insulin injections and infections [Editorial]. BMJ 1981;282:340.
111. Swift PGF, Hearnshaw JR. Insulin injections and infections [Letter]. BMJ 1981;282:1323.
112. Borders LM, Bingham PR, Riddle MC. Traditional insulin-use practices and the incidence of bacterial contamination and infection. Diabetes Care 1984;7: 121-127.
113. Poteet GW, Reinert B, Ptak HE. Outcome of multiple usage of disposable syringes in the insulin-requiring diabetic. Nurs Res 1987;36:350-352.
114. Price JP, Kruger DF, Saravolatz LD, et al. Evaluation of the insulin jet injector as a potential source of infection. Am J Infect Control 1989;17:258-263.
115. Brink SJ, Stewart C. Insulin pump treatment in insulin-dependent diabetes mellitus: children, adolescents, and young adults. JAMA 1986;255:617-621.
116. Chantelau E, Lange G, Sonnenberg GE, et al. Acute cutaneous complications and catheter needle colonization during insulin-pump treatment. Diabetes Care 1987;10:478-482.
117. Bell DS, Ackerson C, Cutter G, et al. Factors associated with discontinuation of continuous subcutaneous insulin infusion. Am J Med Sci 1988;295:23-28.
118. van Faassen I, Razenberg PPA, Simoons-Smit AM, et al. Carriage of Staphylococcus aureus and inflamed infusion sites with insulin pump therapy. Diabetes Care 1989;12:153-155.
119. Carson CC. Infections in genitourinary prostheses. Urol Clin North Am 1989; 16:139-147.
120. Blum MD. Infections of genitourinary prostheses. Infect Dis Clin North Am 1989;3:259-274.
121. Montague DK. Periprosthetic infections. . Urol 1987;138:68-69.
122. Carson CC, Robertson CN. Late hematogenous infection of penile prostheses. . Urol 1988;139:50-52.
123. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host, 3rd ed. New York: Plenum Press, 1994:629-705.
124. Gottesdiener KM. Transplanted infections: donor-to-host transmission with the allograft. Ann Intern Med 1989;110:1001-1016.
125. Bowen PH II, Lobel SA, Caruana RJ, et al. Transmission of human immunodeficiency virus (HIV) by transplantation: clinical aspects and time course analysis of viral antigenemia and antibody production. Ann Intern Med 1988; 108:46-48.
126. Kontoyiannis DP, Rubin RH. Infection in the organ transplant recipient: an overview.Infect Dis Clin North Am 1995;9:811-822.
127. Basgoz N, Rubin RH. Antimicrobial prophylaxis in patients undergoing solid organ transplantation. Curr Clin Top Infect Dis 1995;15:344-364.
128. Sudan D, Sudan R, Stratta R. Long-term outcome of simultaneous kidneypancreas transplantation: analysis of 61 patients with more than 5 years follow-up. Transplantation 2000;69:550-555.
129. Smets YF, van der Pijl JW, van Dissel JT, et al. Infectious disease complications of simultaneous pancreas kidney transplantation. Nephrol Dial Transplant 1997;12:764-771.
130. Rheuman MJ, Rheuman B, Icenogle T, et al. Diabetes and heart transplantation. . Heart Transplant 1988;7:356-358.
131. Peterson PK, Keane WF. Infections in chronic peritoneal dialysis patients. Curr Clin Top Infect Dis 1985;6:239.
132. Steigbigel RT, Cross AS. Infections associated with hemodialysis and chronic peritoneal dialysis. Curr Clin Top Infect Dis 1984;5:124-145.
133. Vas SI. Infections of continuous ambulatory peritoneal dialysis catheters. Infect Dis Clin North Am 1989;3:301-328.
134. Amair P, Khanna R, Leibel B, et al. Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease. . Engl J Med 1982;306:625-630.
135. Madden MA, Zimmerman SW, Simpson DP. Continuous ambulatory peritoneal dialysis in diabetes mellitus: the risks and benefits of intraperitoneal insulin. Am J Nephrol 1982;2:133-139.
136. Kraus ES, Spector DA. Characteristics and sequelae of peritonitis in diabetics and nondiabetics receiving chronic intermittent peritoneal dialysis. Medicine (Baltimore) 1983;62:52-57.
137. Vas SI, Law L. Microbiological diagnosis of peritonitis in patients on continuous ambulatory peritoneal dialysis. . Clin Microbiol 1985;21:522-523.
138. Powe NR, Jaar B, Furth SL, et al. Septicemia in dialysis patients: incidence, risk factors, and prognosis. Kidney Int 1999;55:1081-1090.
139. Arfania D, Everett D, Nolph K, Rubin J. Uncommon causes of peritonitis in patients undergoing peritoneal dialysis. Arch Intern Med 1981;141:61-64.
140. Gilbert DN, Moellering RC Jr, Sande MA, eds. The Sanford guide to antimicrobial therapy, 13th ed. Hyde Park, VT: Antimicrobial Therapy, 2000.
141. Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can't live without them. Kidney Int 1999;56:1-17.
142. Vas SI. Infections associated with peritoneal and hemodialysis. In: Bisno AL, Waldvogel FA, eds. Infections associated with indwelling medical devices . Washington DC: American Society for Microbiology, 1989:215-248.
143. Stevenson KB, Adcox MJ, Mallea MC, et al. Standardized surveillance of hemodialysis vascular access infections: 18-month experience at an outpatient, multifacility hemodialysis center. Infect Control Hosp Epidemiol 2000; 21:200-203.
144. Quarles LD, Rutsky EA, Rostand SG. Staphylococcus aureus bacteremia in patients on chronic hemodialysis. Am J Kidney Dis 1985;6:412-419.
145. Cross AS, Steigbigel RT. Infective endocarditis and access site infections in patients on hemodialysis. Medicine (Baltimore) 1976;55:453-466.
146. Francioli P, Masur H. Complications of Staphylococcus aureus bacteremia: occurrence in patients undergoing long-term hemodialysis. Arch Intern Med 1982;142:1655-1658.
147. Marr KA, Kong L, Fowler VG, et al. Incidence and outcome of Staphylococcus aureus bacteremia in hemodialysis patients. Kidney Int 1998;54:1684-1689.
148. Schwab DP, Taylor SM, Cull DL, et al. Isolated arteriovenous dialysis access graft segment infection: the results of segmental bypass and partial graft excision. Ann Vasc Surg 2000;14:63-66.
149. Bryan CS, Reynolds KL, Metzger WT. Bacteremia in diabetic patients: comparison of incidence and mortality with nondiabetic patients. Diabetes Care 1985;8:244-249.
150. Keane EM, Boyko EJ, Reller LB, et al. Prevalence of asymptomatic bacteriuria in subjects with NIDDM in San Luis Valley of Colorado. Diabetes Care 1988; 11:708-712.
151. Schmitt JK, Fawcett CJ, Gullickson G. Asymptomatic bacteriuria and hemoglobin A1. Diabetes Care 1986;9:518-520.
152. Sawers JS, Todd WA, Kellett HA, et al. Bacteriuria and autonomic nerve function in diabetic women. Diabetes Care 1986;9:460-464.
153. Raz R, Gennesin Y, Wasser J, et al. Recurrent urinary tract infections in postmenopausal women. Clin Infect Dis 2000;30:152-156.
154. Brauner A, Östenson CG. Bacteremia with P-fimbriated Escherichia coli in diabetic patients: correlation between proteinuria and non-P-fimbriated strains. Diabetes Res 1987;6:61-65.
155. Levison ME, Pitsakis PG. Effect of insulin treatment on the susceptibility of the diabetic rat to Escherichia coli-induced pyelonephritis. . Infect Dis 1984; 150:554-560.
156. Groop L, Laasonen L, Edgren J. Renal papillary necrosis in patients with IDDM. Diabetes Care 1989;12:198-202.
157. Eknoyan G, Qunibi WY, Grissom RT, et al. Renal papillary necrosis: an update. Medicine (Baltimore) 1982;61:55-73.
158. Mujais SK. Renal papillary necrosis in diabetes mellitus. Semin Nephrol 1984; 4:40-47.
159. Saiki J, Vaziri ND, Barton C. Perinephric and intranephric abscesses: a review of the literature. West J Med 1982;136:95-102.
160. Plevin SN, Balodimos MC, Bradley RF. Perinephric abscess in diabetic patients. . Urol 1979;103:539-543.
161. Patterson JE, Andriole VT. Renal and perirenal abscesses. Infect Dis Clin North Am 1987;1:907-926.
162. Bova JG, Potter JL, Arevalos E, et al. Renal and perirenal infection: the role of computerized tomography. . Urol 1985;133:375-378.
163. Hutchison FN, Kaysen GA. Perinephric abscess: the missed diagnosis. Med Clin North Am 1988;72:993-1014.
164. Edelstein H, McCabe RE. Perinephric abscess: modern diagnosis and treatment in 47 cases. Medicine (Baltimore) 1988;67:118-131.
165. Bartholomew GA, Rodu B, Bell DS. Oral candidiasis in patients with diabetes mellitus: a thorough analysis. Diabetes Care 1987;10:607-612.
166. Hill LVH, Tan MH, Pereira LH, et al. Association of oral candidiasis with diabetic control. . Clin Pathol 1989;42:502-505.
167. Fisher BM, Lamey P-J, Samaranayake LP, et al. Carriage of Candida species in the oral cavity in diabetic patients: relationship to glycaemic control. . Oral Pathol 1987;16:282-284.
168. Phelan JA, Levin SM. A prevalence study of denture stomatitis in subjects with diabetes mellitus or elevated plasma glucose levels. Oral Surg Oral Med Oral Pathol 1986;62:303-305.
169. Vazquez JA, Sobel JD. Fungal infections in diabetes. Infect Dis Clin North Am 1995;9:97-116.
170. Williams DN, Knight AH, King H, et al. The microbial flora of the vagina and its relationship to bacteriuria in diabetic and non-diabetic women. Br J Urol 1975;47:453-457.
171. Sobel JD. Vulvovaginal candidiasis-what we do and do not know [editorial]. Ann Intern Med 1984;101:390-392.
172. Rein MF, Holmes KK. Nonspecific vaginitis vulvovaginal candidiasis and trichomoniasis. Curr Clin Top Infect Dis 1983;4:281.
173. Roy JB, Geyer JR, Mohr JA. Urinary tract candidiasis: an update. Urology 1984;23:533-537.
174. Frye KR, Donovan JM, Drach GW. Torulopsis glabrata urinary infections: a review. J Urol 1988;139:1245-1249.
175. Frangos DN, Nyberg LM Jr. Genitourinary fungal infections. South Med J 1986;79:455-459.
176. Fisher J, Mayhall G, Duma R, et al. Fungus balls of the urinary tract. South Med J 1979;72:1281-1284.
177. Urinary tract candidosis. Lancet 1988;2:1000-1002.
178. Bibler MR, Gianis JT. Acute ureteral colic from an obstructing renal aspergilloma. Rev Infect Dis 1987;9:790-794.
179. Smith JA, O'Connor JJ. Nasal carriage of Staphylococcus aureus in diabetes mellitus. Lancet 1966;2:776-777.
180. Tuazon CU, Perez A, Kishaba T, et al. Staphylococcus aureus among insulininjecting diabetic patients: an increased carrier rate. JAMA 1975;231:1272.
181. Chandler PT, Chandler SD. Pathogenic carrier rate in diabetes mellitus. Am J Med Sci 1977;273:259-263.
182. Boyko EJ, Lipsky BA, Sandoval R, et al. NIDDM and prevalence of nasal Staphylococcus aureus colonization: San Luis Valley diabetes study. Diabetes Care 1989;12:189-192.
183. Lipsky BA, Pecoraro RE, Chen MS, et al. Factors affecting staphylococcal colonization among NIDDM outpatients. Diabetes Care 1987;10:483-486.
184. Tuazon CU. Skin and skin structure infections in the patient at risk: carrier state of Staphylococcus aureus. Am J Med 1984;76[Suppl 5A]:166-171.
185. Greenwood AM. Astudy of the skin in five hundred cases of diabetes. JAMA 1927;89:774-779.
186. Williams JR. Does diabetes mellitus predispose the patient to the pyogenic skin infections? A study of the etiologic relationship of furunculosis and carbuncle. JAMA 1942;118:1357.
187. Musher DM, McKenzie SO. Infections due to Staphylococcus aureus. Medicine (Baltimore) 1977;56:383-409.
188. Luzar MA, Coles GA, Faller, et al. Staphylococcus aureus nasal carriage and infection in patients on continuous ambulatory peritoneal dialysis. . Engl J Med 1990;322:505-509.
189. Mylotte JM, McDermott C, Spooner JA. Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. Rev Infect Dis 1987;9:891-907.
190. Cluff LE, Reynolds RC, Page DL, et al. Staphylococcal bacteremia and altered host resistance. Ann Intern Med 1968;69:859-873.
191. Watanakunakorn C, Baird IM. Prognostic factors in Staphylococcus aureus endocarditis and results of therapy with a penicillin and gentamicin. Am J Med Sci 1977;273:133-139.
192. Cooper G, Platt R. Staphylococcus aureus bacteremia in diabetic patients: endocarditis and mortality. Am J Med 1982;73:658-662.
193. Sentochnik DE. Deep soft-tissue infections in diabetic patients. Infect Dis Clin North Am 1995;9:53-164.
194. Dellinger EP. Severe necrotizing soft-tissue infections: multiple disease entities requiring a common approach. JAMA 1981;246:1717-1721.
195. Rouse TM, Malangoni MA, Schulte WJ. Necrotizing fasciitis: a preventable disaster. Surgery 1982;92:765-770.
196. Ahrenholz DH. Necrotizing soft-tissue infections. Surg Clin North Am 1968; 68:199-214.
197. Gozal D, Ziser A, Shupak A, et al. Necrotizing fasciitis. Arch Surg 1986;121: 233-235.
198. Freeman HP, Oluwole SF, Ganepola GAP, et al. Necrotizing fasciitis. Am J Surg 1981;142:377-383.
199. Stevens DL. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med 2000;51:271-288.
200. O'Dell K, Shipp J. Fournier's syndrome in a ketoacidotic diabetic patient after intrascrotal insulin injections because of impotence. Diabetes Care 1983; 6:601-603.
201. Spirnak JP, Resnick MI, Hampel N, et al. Fournier's gangrene: report of 20 patients. . Urol 1984;131:289-291.
202. Lamb RC, Juler GL. Fournier's gangrene of the scrotum: a poorly defined syndrome or a misnomer? Arch Surg 1983;118:38-40.
203. Addison WA, Livengood CH III, Hill GB, et al. Necrotizing fasciitis of vulvar origin in diabetic patients. Obstet Gynecol 1984;63:473-479.
204. Stone HH, Martin JD Jr. Synergistic necrotizing cellulitis. Ann Surg 1972; 175:702-711.
205. Swartz MN. Subcutaneous tissue infections and abscesses. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious disease, 3rd ed. New York: Churchill Livingstone, 1990:808-818.
206. Bessman AN, Wagner W. Nonclostridial gas gangrene: report of 48 cases and review of the literature. JAMA 1975;233:958-963.
207. Oscarsson PN, Silwer H. Incidence of pulmonary tuberculosis among diabetics: search among diabetics in the county of Kristianstad. Acta Med Scand Suppl 1958;335:23-48.
208. Rieder HL, Cauthen GM, Comstock GW, et al. Epidemiology of tuberculosis in the United States. Epidemiol Rev 1989;11:79-98.
209. Patel MS. Bacterial infections among patients with diabetes in Papua New Guinea. Med J Aust 1989;150:25-28.
210. Pablos-Mendez A, Blustein J, Knirsch CA. The role of diabetes mellitus in the higher prevalence of tuberculosis among Hispanics. Am J Public Health 1997; 87:574-579.
211. Centers for Disease Control. Screening for tuberculosis and tuberculosis infection in high-risk populations: recommendations of the Advisory Committee for Elimination of Tuberculosis. MMWR 1995;44:18-34.
212. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1994;43(RR-1):1-38.
213. ACP Task Force on Adult Immunization. Guide for adult immunization, 2nd ed. Philadelphia: American College of Physicians, 1990.
214. Centers for Disease Control and Prevention. Influenza and pneumococcal vaccination rates among persons with diabetes mellitus-United States, MMWR Morb Mortal Wkly Rep 1999;48:961-967.
215. Centers for Disease Control. Prevention and control of influenza. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morbid Mortal Wkly Rep 1990;39:1-15.
216. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982;142:85-89.
217. Diepersloot RJA, Bouter KP, Beyer WEP, et al. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologica 1987;30:397-401.
218. Lederman MM, Rodman HM, Schacter BZ, et al. Antibody response to pneumococcal polysaccharides in insulin-dependent diabetes mellitus. Diabetes Care 1982;5:3-96.
219. Pozzilli P, Gale EAM, Visalli N, et al. The immune response to influenza vaccination in diabetic patients. Diabetologica 1986;29:850-884.
220. Feery BJ, Hartman LJ, Hampson AW, Proietto J. Influenza immunization in adults with diabetes mellitus. Diabetes Care 1983;6:475-478.
221. Colquhoun AJ, Nicholson KG, Botha JL, et al. Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 1997;119:335-341.
222. Fedson DS. Pneumococcal vaccine. In: Plotkin SA, Mortimer EA Jr, eds. Vaccines. Philadelphia: WB Saunders, 1988:271-299.
223. Butler JC, Breiman RF, Campbell JF, et al. Pneumococcal polysaccharide vaccine efficacy. An evaluation of current recommendations. JAMA 1993;270: 1826-1831.
224. Spika JS, Fedson DS, Facklam RR. Pneumococcal vaccination: controversies and opportunities. Infect Dis Clin North Am 1990;4:11-27.
225. Beam TR Jr, Crigler ED, Goldman JK, et al. Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA 1980;244: 2621-2624.
226. Centers for Disease Control. Pneumococcal polysaccharide vaccine. MMWR Morbid Mortal Wkly Rep 1989;38:64-68,73-76.
227. Centers for Disease Control. Protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 1990;39:1-26.
228. Pozzilli P, Arduini P, Visalli N. Reduced protection against hepatitis B virus following vaccination in patients with type I (insulin-dependent) diabetes. Diabetologia 1987;30:817-819.
229. Hadler SC. Vaccines to prevent hepatitis B and hepatitis A virus infections. Infect Dis Clin North Am 1990;4:29-46.
230. Marseglia GL, Scaramuzza A, d'Annunzio G, et al. Successful immune response to a recombinant hepatitis B vaccine in young patients with insulindependent diabetes mellitus. Diabet Med 1996;13:630-633.
231. Golden SH, Peart-Vigilance C, Kao WH, et al. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 1999;22:1408-1414.
232. Furnary AP, Zerr KJ, Grunkemeier GL, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67:352-360.
233. Pomposelli JJ, Baxter JK 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. J Parenter Enteral Nutr 1998;22:77-81.
234. Khaodhiar L, McCowen K, Bistrian B. Perioperative hyperglycemia, infection or risk? Curr Opin Clin Nutr Metab Care 1999;2:79-82.